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In this month’s JCSM, we see the publication of two excellent
studies assessing the relationship between CT body composi-
tion (BC) analysis, systemic inflammation (SI), and survival in
patients with colorectal cancer. Both studies identify markers
of worsened BC and SI as independent, and potentially
additive, determinants of patient prognosis, over and above
standard clinical prognostic measures of tumour staging. This
editorial will describe additional lessons that may be gleaned
by comparing the epidemiology, methodology, and interpre-
tation of these two studies and other human BC projects in
cancer. Moreover, it will highlight the emerging importance
of host phenotyping in the delivery of modern oncological
care.
The authors of our two considered papers this month
should be congratulated for the aims, scope, and integrity
of their studies. Although the emphases of the two papers
are subtly different (in part reflecting the research histories
of the respective groups), the findings are essentially, and re-
assuringly, similar. Dolan et al.1 discuss their findings with re-
gard to a large cohort of Scottish patients in the early stage of
the cancer journey, undergoing elective primary surgery for
colorectal cancer (n = 650). In comparison, van Dijk et al.2
consider Dutch patients further along the cancer pathway,
undergoing surgical resection of colorectal liver metastases
(CLRM; n = 97). In both studies, worsened BC as assessed
by staging CT and SI were each independent prognostic fac-
tors in determining overall patient survival during median
follow-up periods of several years. Furthermore, it was
shown that adverse BC phenotypes [including low skeletal
muscle index (SMI; sarcopenia) or low skeletal muscle
radiodensity (SMD)] could exist independently from SI (and
vice versa). In the Dolan study, measures of BC were still
weakly associated with overall survival even after stratifica-
tion of patients in to different SI groups. Moreover, in the
van Dijk study, a composite host phenotype consisting of ad-
verse BC and SI was shown to have an additive and
synergistic deleterious effect on survival (HR of death >4)
and was also statistically independent of the Fong clinical
prognostic score (a 5-point score that assesses nodal status
of the primary tumour, the disease-free interval, the size
and number of secondary hepatic tumours, and the preoper-
ative serum CEA level).
Despite the apparent separation of survival impact, inter-
estingly, the presence of SI still appears to be correlated
with worsened BC. Thus, the relationship between BC and
SI in cancer appears to be a complex one, for which direct
causality is difficult to prove. To quote Dolan et al., ‘Such
cross sectional data cannot determine whether a low SMI
or SMD results in the presence of SI or whether the pres-
ence of SI results in low SMI or SMD. From the present re-
sults, it is clear that a low SMI, SMD or both can occur in
the absence of SI.
So why is causation, and the role of SI as a driver of nu-
tritional depletion, so difficult to prove in human studies?
When placed side by side, studies such as the two published
in this month’s edition offer us the opportunity to help an-
swer this question by providing valuable insights into the
methodology, epidemiology, and interpretation of multivari-
able BC data in human cachexia research. Initially, one can
compare and contrast the potential idiosyncrasies of patient
populations across different studies. In the two considered
studies this month, disease status and geography appear
to have had profound effects on the prevalence of the ex-
perimental variables in question (namely, SI and BC). With
regard to the ‘earlier’ patients in the Dolan study, only ap-
proximately 25% of patients had SI [evidenced by modified
Glasgow Prognostic Score (mGPS) 1 or 2], whereas the im-
plied prevalence of SI in the ‘later’ van Dijk cohort was al-
most twice as high (CRP ≥ 5 mg/L = 48%). Some of the
observed disparities may be due to alternative approaches
to SI measurement: the mGPS requires a serum CRP level
>10 mg/L, compared with the ≥5 mg/L cut-off used by
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van Dijk et al. However, the results also imply that SI is as-
sociated with disease progression and that patients with
metastatic disease are more likely to have elevated CRP,
an observation noted in previous studies.
With regard to BC, approximately 47–60% of patients in
the Dolan study exhibited myosteatosis (by CT criteria),
whereas, on the whole, patients were not frankly
myosteatotic in the van Dijk study. Assuming that progressive
myosteatosis is associated with cancer cachexia,3 this obser-
vation seems counterintuitive considering the position of
the respective patient populations on their disease trajectory.
Although patients in the Dolan study were likely to be slightly
older on average than the van Dijk study, and there was a
higher preponderance of females, this propensity of
myosteatosis likely reflects the background inequalities in
BC between a deprived Scottish population (co-morbidity
88%; visceral adiposity 73%) compared with a leaner,
possibly healthier, Dutch one (visceral adiposity 52%). The
authors do not comment specifically on the survival impact
of sarcopenic obesity in their populations, a body habitus
that has been identified as a negative prognostic indicator
in some surgical and cancer cohorts.4 Further studies in this
area will help to elucidate the onlay of the obesity paradox
on patients with cancer and cachexia. CT BC data should
always be analysed with respect to patient sex and BMI,5
but such unanticipated differences in BC across international
populations also highlight the importance of examining BC
data in the context of the local geographical and ethnic
norms, and they strongly support the aim of current
multicentre strategies to generate international, disease-
specific CT BC cutpoints (e.g. INSPECT study for oesopha-
geal cancer).
In a similar way to the SI data, some of the observed dis-
parities in BC status might also be the result of alternative
methods of data analysis. Dolan et al. used a diverse range
of published cutpoints to establish their CT definitions of
sarcopenia and myosteatosis. In comparison, van Dijk et al.
used Z-scores (to indicate how many standard deviations an
element is from the mean) derived from CT values of a larger
cohort of patients with metastatic colorectal cancer.4 Al-
though both studies used similar source data for their analyt-
ical techniques (see Martin et al.5), the actual CT cutpoints
employed will have differed. These varying, and apparently
valid, approaches to BC analysis reinforce the current calls
for technical standardization in CT BC. At the present time,
even the terminology surrounding CT BC can be confusing.
For example, sarcopenia, a term used classically to mean a
primary and dynamic age-related deterioration in muscle
mass and function, is now often meant to mean a static,
one-off measure of muscle cross-sectional area or volume
on a single CT. Likewise, across the two studies considered
this month, various terms have been used to represent low
average Hounsfield units across muscles, including reduced
muscle attenuation or muscle radiodensity, leading to poor
muscle quality and myosteatosis, the latter two terms
reflecting assumptions rather than true measures of muscle
power, strength, or fat infiltration. In short, attempts at stan-
dardization of language, as well as technique, would also be
beneficial.
In the past few years, there has been a tendency for surgi-
cal publications to simply concentrate on a single measure of
CT BC (usually either SMI or SMD) or to utilize less well-vali-
dated methods of BCA, such as psoas cross-sectional area
rather than L3 analysis. The authors of the studies reviewed
this month should be applauded for taking the opportunity
to perform rigorous analyses of all of the well-described
facets of CT BC, including measurements of muscle, fat, vol-
ume, and attenuation. However, the authors do identify the
lack of repeated CT measures as a potential shortcoming of
their studies. Without repeated assessments, ‘it is difficult
to distinguish BC features that are constitutional from those
that are secondary to the disease state’. Sequential assess-
ments would allow the interpretation of dynamic wasting
and the identification of different wasting phenotypes that
describe the natural history of cachexia, the negative impact
of treatment, and the relationship with survival.6 They would
also help account for variations in local geographical norms.
In summary, there is added value to be gained from such
exercises in study comparison. However, to return to the be-
ginning, the crucial and invaluable findings of the present
studies are that they identify host phenotypes (including BC
and SI) as major determinants of patient survival that are
equivalent in effect to standard clinical assessments of tu-
mour phenotype (e.g. disease stage). Van Dijk et al. have cho-
sen to employ the term ‘tumour biology’ rather than ‘tumour
phenotype’, and they state that the effect of tumour biology
on prognosis in CRLM is ‘well known’. However, I would ar-
gue that this is not entirely the case. The Fong score (as a
measure of tumour biology) is not wholly representative of
biological processes; rather, it is an indirect composite mea-
sure of disease burden and some aspects of metastatic be-
haviour. The field of tumour biology, including analyses of
tumour genetics, immunology, cell heterogeneity/stromal
cells, and metastatic potential, is largely unexplored in rela-
tion to human wasting, the pathogenesis of SI, or the deter-
mination of survival. In cachexia research, only recently are
we beginning to investigate the roles of tumour-specific me-
diators, extracellular vesicles,7 and the roles of host immune
cells8 (e.g. tumour-associated macrophages). Without cancer,
there can be no cancer cachexia, and thus, the field of
tumour biology is a key unmet need in cachexia research. Ex-
ploration of this area is even more pressing during the cur-
rent era of immune checkpoint inhibitors, which have
revolutionized treatments in some tumour types (e.g. PD-1
and PDL-1 inhibitors). At this stage, we are not even fully
cognizant of the natural history of BC along varying treat-
ment pathways, and prospective studies are an aspiration
for the future.
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In conclusion, van Dijk et al. assert that ‘the true value of
our observations is that we have recognized independent
host-derived features that can adversely affect survival in
addition to tumor-derived features’, whereas Dolan et al.
support the ‘… incorporation of the SMI, SMD and mGPS
as part of the clinical and nutritional assessment in patients
with cancer’. Both sets of authors highlight the need for
host-specific strategies for intervention. These studies
underline the current lack of host phenotyping in modern
oncological care. A fundamental paradigm shift is required
to incorporate the relevance of host phenotype in clinical
prognostication, treatment decisions, and the calculation of
chemotherapy dosing. The final message is that we should
stage the tumour and stage the host and then treat the
tumour and treat the host.
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